MSD India

What MSD India does

MSD India operates as MSD Pharmaceuticals Private Limited, a wholly-owned subsidiary of Merck & Co., Inc. (Rahway, NJ, USA) that commercializes pharmaceutical products in India. The source data centers on the company's 'Let's Fight HPV' educational platform (letsfighthpv.com), which provides information about HPV infection, vaccine eligibility, and HPV-related cancer prevention, targeting parents of children aged 9 and above, women across age groups, and healthcare providers including pediatricians and gynecologists. The website is restricted to residents of India aged 18 or older, and the India entity employs 177 staff.

The underlying technology is MSD's HPV vaccine platform, which stimulates the immune system to produce antibodies against high-risk HPV types (16, 18) and low-risk types (6, 11). According to the source, the vaccine can reduce risk of certain HPV-related cancers and genital warts by 80-90%, and vaccination between ages 9-15 produces nearly 2x better immune response compared to vaccination after age 15. The vaccine has been administered to over 100 million people across 170+ countries since 2006, with 135 million doses distributed worldwide. India represents a significant market: cervical cancer is the 2nd most common cancer in women aged 15-44 in India, with 1,23,907 annual cases linked to high-risk HPV types.

MSD India's business model does not involve direct-to-consumer vaccine sales; instead, it relies on healthcare provider networks (gynecologists and pediatricians) to administer vaccines. The go-to-market leverages a multi-channel awareness strategy comprising an educational website, blog content, a WhatsApp-based doctor finder (powered by Nivi), and corporate social media presence across Instagram, Facebook, YouTube, Twitter/X, and LinkedIn. Revenue is generated indirectly through vaccine sales via prescriber channels, with specific pricing not publicly disclosed. The company holds multiple global privacy and data protection certifications including GDPR compliance, EU Binding Corporate Rules, US-EU Privacy Shield, and APEC Cross Border Privacy Rules.

Name

MSD India

Legal name

MSD Pharmaceuticals Private Limited

Website

https://letsfighthpv.com

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

MSD India (MSD Pharmaceuticals Private Limited) is a subsidiary of Merck & Co., Inc. that commercializes HPV vaccines in India via healthcare provider networks, operating the 'Let's Fight HPV' educational platform to drive awareness among parents, women, and clinicians.

Ownership category

akta.pro rank

Product category

Pharmaceuticals — Vaccines (HPV)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Pediatric Vaccines (HLAIAEAA), Public & Private Vaccine Provider Networks (Clinics/Pharmacies/Physicians) (HLAJAHAB)

Keywords

• HPV vaccination
• Pharmaceutical manufacturing
• Cancer prevention
• Vaccine awareness
• Immunization education

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Distribution channels2 records

Marketing channels8 records

Core offering

MSD India, through MSD Pharmaceuticals Private Limited, provides HPV vaccines and operates the "Let's Fight HPV" educational platform (letsfighthpv.com) that educates parents, women, and healthcare providers about HPV infection, vaccination, and prevention of HPV-related cancers (cervical, vaginal, vulvar, anal) and genital warts. The vaccine covers high-risk HPV types 16 and 18 and low-risk types 6 and 11, with clinical evidence showing 80–90% risk reduction for HPV-related genital warts and certain cancers and nearly 2x better immune response when administered at age 9–15.

Product overview

MSD India operates an educational platform focused on HPV awareness and prevention. The primary offering is the 'Let's Fight HPV' website (letsfighthpv.com), which provides educational resources about HPV infection, HPV vaccination, and HPV-related cancers. The platform includes informational pages about HPV transmission, prevention methods, vaccination schedules, and frequently asked questions, as well as blog content addressing topics such as adolescent health, vaccine myths, and cancer prevention for young women.

Differentiator

Problem solved

Functional benefit

Brands

• Let's Fight HPV: An educational initiative by MSD India focused on HPV awareness, prevention through vaccination, and cancer prevention education.

Products and services

• Let's Fight HPV Educational Platform

Quantifiable outcome

• HPV vaccination can reduce the risk of HPV-related genital warts and certain cancers by 80-90%
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Serum Institute of India: Serum Institute launched Cervavac, India's first indigenous HPV vaccine, positioning as a lower-cost alternative to MSD's Gardasil. It targets the same pediatric/adolescent population and competes directly in both private channels and potential government tenders.
• GSK India (GlaxoSmithKline Pharmaceuticals): GSK India markets Cervarix, the principal direct HPV vaccine competitor to MSD's Gardasil in India. Both run patient/physician awareness initiatives targeting adolescent HPV vaccination and compete head-to-head for pediatrician and gynecologist prescriptions in India's private market.

Broad incumbents

• Cipla: Cipla is one of India's largest pharmaceutical companies with a broad portfolio across respiratory, oncology, and preventive health. It engages similar healthcare provider networks and could expand into HPV-related preventive health education.
• Pfizer India: Pfizer India is a major multinational pharmaceutical subsidiary with a broad vaccines and therapeutics portfolio. While not an HPV vaccine marketer in India, it competes for the same institutional buyers, physician relationships, and patient awareness mindshare.
• Bharat Biotech: Bharat Biotech is a leading Indian vaccine manufacturer with a broad pediatric and adult vaccine portfolio. It is an established competitor in India's vaccine market and could expand into HPV-related products, overlapping with MSD India's prescriber relationships and channels.
• Sanofi India: Sanofi India operates a sizable vaccines and pharmaceuticals business in India, engaging the same pediatrician and gynecologist prescriber base as MSD India. Its pediatric vaccine franchise overlaps with MSD's HPV awareness targeting of adolescents aged 9+.

Emerging players

• Biological E: Biological E is an Indian vaccine manufacturer scaling its pediatric and adolescent vaccine portfolio, including HPV-related product development. It competes with MSD India for pediatric vaccine channel share and could emerge as a future HPV competitor.

Others

• Indian Academy of Pediatrics (IAP): IAP is a professional body of Indian pediatricians that issues immunization recommendations including HPV vaccination starting at age 9. It is a key endorser and prescriber-influencing authority for MSD India's HPV awareness initiative and shapes demand for adolescent HPV vaccines.
• Federation of Obstetric and Gynaecological Societies of India (FOGSI): FOGSI is the apex professional body of Indian gynecologists and obstetricians that recommends HPV vaccination for women. It is a key endorser of MSD India's HPV awareness platform and a critical prescriber-influencing channel for women's HPV vaccination.
• World Health Organization (WHO) India: WHO shapes global and national HPV vaccination policy, including the recommendation for HPV vaccination starting at age 9 that MSD India's platform references. WHO guidance influences UIP inclusion decisions that materially affect MSD India's addressable HPV market in India.

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MSDIndia_OFCL
• YouTubeyoutube.com/@msdindia-official
• Facebookfacebook.com/msdindia.official
• LinkedInlinkedin.com/company/msdindiaofficial
• Instagraminstagram.com/msdindia.official

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD India